PDF
Citation
Print
INTRODUCTION
Rheumatoid arthritis (RA) is a chronic autoimmune disease that affects multiple joints, resulting in structural damage, functional disability, and reduced quality of life [1]. Radiographic progression (RP) is one of the most important indicators of disease severity and cumulative disease activity [2]. Disease activity over time is thought to lead to the occurrence of RP; therefore, clinical studies investigating novel medications as potential treatment for RA have focused on whether the candidates prevent RP as well as attenuating disease activity. A variety of biologic agents and small molecule inhibitors targeting disease-related cytokines and intra-cellular signaling pathways have been developed and shown to be effective at slowing RP [3,4]. Promising results from some large-scale trials suggest that new therapeutic modalities prevent RP almost completely [5]. However, randomized clinical trials and experience in real-world clinical settings show that despite good responses, according to composite indices that are representative of RA activity, RP can occur even with proper management [6].
Diverse composite indices, including the Disease Activity Score with 28 joint counts (DAS28), Clinical Disease Activity Index (CDAI), and Simplified Disease Activity Index (SDAI), are used as therapeutic targets for treat-to-target (T2T) strategies for RA [7]. Composite indices for measuring disease activity comprise different combinations of separate clinical and laboratory parameters, including subjective patient-reported outcomes and objective serum markers such as the erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) levels. Although disease composite indices are used as a standard tool to determine RA activity, recent studies demonstrate that even when these indices suggest that RA patients are in clinical remission, 20%~30% still show RP [8]. Subclinical joint inflammation on musculoskeletal ultrasonography is also observed in more than half of RA patients in clinical remission [9]. Moreover, levels of the acute phase reactant CRP, which is more easily used as a biomarker for RA activity and is a component of DAS28-CRP, can fall after treatment with biologic agents (particularly with interleukin-6 inhibitors), regardless of the patients’ symptoms [10]. Taken together, these reports raise some important questions about whether it is still valid to use these indices as a sole therapeutic guideline for daily practice, particularly in the ‘post-biologic’ era; therefore, alternative strategies that more sensitively represent RP are needed for optimal management of RA patients [11,12].
To make optimal therapeutic plans, it is important to identify subgroups of RA patients with a poor prognosis who progress rapidly and require aggressive treatment from the beginning. High titers of rheumatoid factor (RF) and anti-citrullinated protein antibodies (ACPA), as well as markers of RA activity (e.g., DAS28, ESR, and CRP), at presentation are regarded as the major predictors of RP during the early phase of RA [13]. Post-hoc analyses of several clinical trials, however, demonstrate that cumulative values for these laboratory and clinical parameters measured at different time-points correlate with RP, although no study has made a direct comparison between one-off and cumulative measurements as a predictor of poor outcome [14]. Moreover, many predictors for RP were identified in well-designed clinical trials conducted in the pre-biologic era [15]; however, it is not clear which parameter(s) is the best predictor of RP in the current T2T strategies with various novel biologic agents.
In the present study, we hypothesized that cumulative measurement of RA activity would better reflect RA progression than measurement at a single time point also in the post-biologic era, as was done in the pre-biologic era. To address this, we investigated which parameter(s) predominantly influences RP in daily clinical practice, and tried to collect clinical and laboratory information from a prospective RA cohort. In addition to baseline values, we calculated cumulative values for each parameter in a time-integrated and averaged manner and then determined whether they better represent RP than a single value.
Go to : 
MATERIALS AND METHODS
Study population
All subjects, samples, and related clinical information were obtained from a prospective cohort of RA patients, all of whom had been monitored regularly at Seoul St. Mary’s Hospital between January 2015 and December 2020. All patients were diagnosed as RA by rheumatologists, including both early and established RA, and met the 2010 RA classification criteria of the American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) [16]. To evaluate the occurrence of RP, subjects with available plain radiographs of both hands and both feet taken at two separate time-points at least 12 months apart were included. Median values of time intervals between two separate x-ray assessments in each subject were about 15 months (Table 1). In addition, only subjects who visited our rheumatology department at least three times during the period between the acquisition of the two X-ray images were included. At each visit, clinical information such as disease activity indices and laboratory values were assessed, and serum was collected. All subjects provided informed consent in accordance with the principles of the Declaration of Helsinki. The study protocol was approved by the Institutional Review Board of Seoul St. Mary’s Hospital of the Catholic University of Korea (approval number: KC20SISI0467). Finally, of 351 RA patients included in the cohort, 117 met the criteria for inclusion in the present study and the others were excluded because of lack of clinical information including radiographs or cumulative laboratory data.
Table 1
Baseline demographic information and medication status
| Variable | Total (n=117) | RP (+) (n=20) | RP (−) (n=97) | p-value |
|---|---|---|---|---|
| Age (yr) | 57 (49~65) | 55 (46~63) | 57 (49~66) | 0.411 |
| Female | 102 (87.2) | 17 (85.0) | 85 (87.6) | 0.720 |
| Body mass index (kg/m2) | 22.8 (20.6~24.9) | 22.4 (20.7~24.3) | 22.9 (20.6~25.0) | 0.728 |
| Disease duration (yr) | 6 (1~13) | 7 (3~14) | 5 (1~13) | 0.606 |
| X-ray f/u duration (mo) | 15 (13~19) | 16 (13~23) | 15 (13~19) | 0.588 |
| Smoking | 1 (0.9) | 1 (5.0) | 0 (0) | 0.171 |
| Medication status | ||||
| Glucocorticoid use | 88 (75.2) | 13 (65.0) | 75 (77.3) | 0.263 |
| Pd equivalent (mg) | 5.0 (2.5~5.0) | 5.0 (2.5~7.5) | 5.0 (2.5~5.0) | 0.378 |
| csDMARDs | ||||
| Methotrexate | 73 (62.4) | 13 (65.0) | 60 (61.9) | 0.792 |
| Leflunomide | 55 (47.0) | 11 (55.0) | 44 (45.4) | 0.432 |
| Hydroxychloroquine | 62 (53.0) | 12 (60.0) | 50 (51.5) | 0.490 |
| Sulfasalazine | 7 (6.0) | 0 (0) | 7 (7.2) | 0.602 |
| bDMARDs or tsDMARDs | 55 (47.0) | 11 (55.0) | 44 (45.4) | 0.432 |
| Tocilizumab | 25 | 6 | 19 | |
| Abatacept | 18 | 3 | 15 | |
| Etanercept | 4 | 0 | 4 | |
| Adalimumab | 3 | 0 | 3 | |
| Tofacitinib | 3 | 2 | 1 | |
| Baricitinib | 2 | 0 | 2 | |
| DAS28 status* | ||||
| Remission | 49 (41.9) | 6 (20.0) | 43 (44.3) | |
| LDA | 17 (14.5) | 3 (15.0) | 13 (14.4) | |
| MDA | 32 (27.4) | 6 (30.0) | 26 (26.8) | |
| HDA | 19 (16.2) | 4 (20.0) | 15 (15.5) | |
| MDA or HDA | 51 (43.6) | 10 (50.0) | 41 (42.3) | 0.525 |
| DAS28 change† | ||||
| Stable | 72 (61.5) | 14 (70.0) | 58 (59.8) | |
| Improvement | 38 (32.5) | 5 (25.0) | 33 (34.0) | |
| Deterioration | 7 (6.0) | 1 (5.0) | 6 (6.2) | |
| Target achievement‡ | 96 (82.1) | 14 (70.0) | 82 (84.5) | 0.196 |
Values are presented as median (interquartile range) or number (%). RP: radiographic progression, f/u: follow up, Pd: prednisolone, csDMARDs: conventional synthetic disease modifying anti-rheumatic drugs, bDMARDs: biologic disease modifying anti-rheumatic drugs, tsDMARDs: targeted synthetic disease modifying anti-rheumatic drugs, DAS28: disease activity score with 28 joint counts, LDA: low disease activity, MDA: moderate disease activity, HDA: high disease activity, ESR: erythrocyte sedimentation rate. *DAS28 status was evaluated at baseline and remission, LDA, MDA, and HDA were defined according to DAS28-ESR. †DAS28 changes defined as ‘Stable’ indicate no interval change in the DAS28 during the study period. ‘Improvement’ denotes a change from MDA or HDA to remission or LDA during the study periods. ‘Deterioration’ denotes a change from remission or LDA to MDA or HDA. ‡Target achievement is defined as achievement of remission or LDA at the last visit.
Radiographic assessment
X-ray images of both hands and both feet were scored using the total Sharp score (mTSS, scores ranging from 0 to 448), as modified by van der Heijde [17]. Two experienced rheumatologists, both of whom were blinded to all clinical information, assessed the mTSS on all images independently at the same time. Inter-observer agreement was 0.93, estimated as an intra-class correlation coefficient between the two scores for the same image, as assessed by both observers. Interval changes in the mTSS between two images from the same subject (at baseline and follow up) were denoted as ΔmTSS. We used the mean values of ΔmTSS between the two readers as the primary outcome. Occurrence of RP, abbreviated as RP (+), was defined when the mean ΔmTSS from the two readers was ≥2 during a follow-up period of 12 months.
Clinical parameters and cumulative values
All clinical variables potentially related to RP were collected from the cohort database, including RF levels and ACPA titers, medication status, the tender joint counts (TJC) and the swollen joint counts (SJC) based on 28 joints, and the DAS28-ESR. Cumulative values for each clinical parameter were calculated using a time-integrated and averaged approach, as described previously [18]. The area under the curve (AUC) for each time-point was included in each clinical parameter using the ‘trapezoidal’ rule, as described previously [18]. For example, if a certain parameter was measured as Y1 and Y2 at the time points of T1 and T2, respectively, the cumulative value for T1 and T2 was calculated as (Y1+Y2)×(T2−T1)/2. The unit of time interval was defined as 1 month. Because the follow-up periods for each subject were different (Table 1), all cumulative values were standardized by being adjusted as the averaged values over 12 months.
Enzyme-linked immunosorbent assay (ELISA)
Several soluble factors have been suggested as novel biomarkers representing disease activity based on their immunological roles in RA pathogenesis. We previously demonstrated that soluble CD14 (sCD14) levels are related to disease activity of RA [19]. Another report also showed sCD14 levels are increased in RA and correlate with disease activity [20]. Therefore, we chose serum sCD14 as the potential biomarker predicting radiographic progression of RA in this study. Serum sCD14 concentrations were measured in an ELISA (R&D Systems, Inc., Minneapolis, MN, USA). Serum samples were obtained from each subject at every visit.
Statistical analysis
All statistical analyses were performed using IBM-SPSS Statistics, version 24.0 (IBM Co., Armonk, NY, USA), and all figures were drawn using GraphPad Prism, version 8.0 (GraphPad software, San Diego, CA, USA). Continuous variables were expressed as the median and interquartile range and were analyzed using the Mann–Whitney U-test due to non-normal distribution of data. Categorical variables were analyzed using the chi-square test or Fisher’s exact test. Correlations between clinical variables were analyzed using Spearman’s rank correlation coefficient test. Uni-variable and multi-variable logistic regression analyses were carried out to identify clinical factors predicting RP. Variables with a p-value<0.1 in uni-variable analyses were included in multi-variable analyses. A p-value<0.05 was considered significant.
Go to :
RESULTS
Demographic, medications, and RA activity at baseline
Among the 117 subjects who fulfilled the inclusion criteria, 20 had RP, and the other 97 patients showed no evidence of RP [RP (−)]. There was no difference between the RP (+) group and the RP (−) group with respect to the median values for age, body mass index, disease duration, X-ray follow-up duration, and sex distribution (Table 1). The median disease duration of RA patients was about 6 years. Most patients were taking about 5 mg glucocorticoids (an equivalent dose of prednisolone), plus one conventional synthetic disease modifying anti-rheumatic drug (csDMARDs) such as methotrexate, leflunomide, or hydroxychloroquine. About half of the subjects were receiving biologic DMARDs (bDMARDs) or targeted synthetic DMARDs (tsDMARDs). Tocilizumab and abatacept were more frequently applied in study subjects than other types of bDMARDs. Nevertheless, overall medication status was similar between the RP (+) and RP (−) groups (Table 1). There was no difference in the proportions of patients with moderate disease activity or high disease activity (HDA) according to DAS28-ESR at baseline. In addition, there was no difference between the two groups with respect to the percentage of patients who achieved the disease activity target, defined as remission or low disease activity (LDA), after a mean follow-up period of 15 months (Table 1).
Effect of baseline RA activity-associated variables on RP
The median value for the mTSS in the RP (+) group was significantly higher than that of the RP (−) group (p = 0.022), suggesting that RA patients with more severely damaged joints in the hand and foot X-rays are at greater risk of RP during follow-up. However, at baseline, the median values of DAS28-ESR and its constituents (i.e., the TJC, SJC, ESR, and visual analog scale) were not significantly different between the RP (+) and RP (−) groups (Table 2). At the beginning of the study, there was no difference in RF levels or ACPA positivity with a high titer between the two groups. Moreover, the ESR and CRP level, both of which are representative blood biomarkers of RA activity, as well as serum sCD14 concentrations at baseline were not predictive of RP occurrence.
Table 2
Baseline disease activity variables
| Variable | Total (n=117) | RP (+) (n=20) | RP (–) (n=97) | p-value |
|---|---|---|---|---|
| Tender joint count | 1 (0~4) | 1 (0~4) | 1 (0~3) | 0.362 |
| Swollen joint count | 0 (0~2) | 1 (0~4) | 0 (0~2) | 0.101 |
| Visual analog scale | 50 (30~70) | 45 (35~68) | 50 (30~70) | 0.785 |
| DAS28-ESR | 2.94 (1.80~4.65) | 3.20 (1.93~4.68) | 2.90 (1.75~4.65) | 0.480 |
| Baseline mTSS | 3 (0~18) | 8 (1~52) | 2 (0~16) | 0.022 |
| WBC count (×103/mm3) | 6.48 (5.08~7.64) | 6.61 (4.34~8.01) | 6.48 (5.45~7.52) | 0.534 |
| Hemoglobin (g/dL) | 13.0 (12.2~13.7) | 13.1 (12.5~14.0) | 13.0 (12.1~13.6) | 0.467 |
| Platelet count (×103/mm3) | 256 (207~315) | 276 (222~334) | 254 (206~315) | 0.259 |
| Albumin (g/dL) | 4.1 (3.9~4.4) | 4.1 (3.9~4.4) | 4.2 (3.9~4.4) | 0.788 |
| RF (IU/mL) | 76.7 (25.7~182.0) | 48.9 (18.7~461.9) | 77.8 (27.1~171.4) | 0.775 |
| RF positivity | 93 (79.5) | 15 (75.0) | 78 (80.4) | 0.556 |
| RF high positivity* | 66 (56.4) | 9 (45.0) | 57 (58.8) | 0.258 |
| ACPA positivity | 31/37 (83.8) | 5/6 (83.3) | 26/31 (83.9) | 0.999 |
| ACPA high positivity* | 29/37 (78.4) | 5/6 (83.3) | 24/31 (77.4) | 0.999 |
| ESR (mm/h) | 14 (3~31) | 19 (3~48) | 12 (3~31) | 0.561 |
| CRP (mg/dL) | 0.19 (0.04~1.12) | 0.16 (0.04~2.22) | 0.21 (0.04~1.07) | 0.828 |
| sCD14 (pg/mL) | 1,961 (1,725~2,392) | 2,071 (1,833~2,300) | 1,922 (1,714~2,431) | 0.588 |
Values are presented as median (interquartile range) or number (%). RP: radiographic progression, DAS28: Disease Activity Score 28, ESR: erythrocyte sedimentation rate, mTSS: modified total Sharp score, WBC: white blood cell, RF: rheumatoid factor, ACPA: anti-citrullinated protein antibody, ESR: erythrocyte sedimentation rate, CRP: C-reactive protein, sCD14: soluble CD14. *High positivity is defined as >3× the upper limit of normal.
Effects of cumulative RA activity-related variables on RP
We postulated that cumulative values during follow-up would be more useful for predicting the occurrence of RP than a single value measured at each visit. To prove our hypothesis, we calculated cumulative values for each clinical variable potentially associated with RA activity and compared data from the RP (+) and RP (−) groups. Among the disease activity-related variables examined, cumulative DAS28-ESR, TJC, SJC, and serum sCD14 values were significantly higher in the RP (+) group than in the the RP (−) group, but there was no difference in the cumulative RF, ESR, and CRP values (Figure 1A~G). The cumulative SJC was the most notable variable with the lowest p-value, indicating that it is the most predictive factor of RP (Figure 1H). By contrast, the cumulative values for white blood cell count, hemoglobin concentration, platelet count, and serum albumin level, did not predict RP (data not shown).
 | Fig. 1Time-integrated cumulative values of clinical parameters related to rheumatoid arthritis disease activity. (A~G) Cumulative values of RF, ESR, CRP, DAS28-ESR, TJC, SJC, and sCD14. (H) Heatmap showing the p-value represented by –log (p-value). Bars indicate the median and interquartile ranges. All statistical analyses were performed using the Mann–Whitney U-test. RP: radiographic progression, RF rheumatoid factor, ESR: erythrocyte sedimentation rate, CRP: C-reactive protein, DAS28: Disease Activity Score 28, TJC: tender joint count, SJC: swollen joint count, sCD14: soluble CD14, mTSS: modified total Sharp score. *p<0.05, ***p<0.001.
|
Next, we carried out multi-variable analysis of the variables at baseline plus the cumulative values with a p-value<0.1. The results identified mTSS at baseline and the cumulative SJC value as significant predictors of RP (Table 3). Moreover, receiver operating characteristic curve analysis revealed that the baseline mTSS, cumulative TJC, cumulative SJC, and cumulative DAS28-ESR showed a significant association with RP (Figure 2). Interestingly, the cumulative SJC showed the highest AUC (0.720), with a sensitivity of 0.650 and a specificity of 0.691 (Figure 2), suggesting that it has the best predictive performance for discriminating RP (odds ratio [95% confidence interval]=1.107 [1.031~1.189], p=0.005). The cut-off value at which the cumulative SJC predicted occurrence of RP was 6, indicating that if the total SJC over the following 12 months is >6, then there should be an increase in the mTSS of more than two points.
 | Fig. 2Diagnostic performance of the baseline mTSS, cumulative SJC, cumulative TJC, and cumulative DAS28-ESR for discriminating radiographic progression (RP). (A) Receiver operating characteristic curves of baseline mTSS, cumulative SJC, cumulative TJC, and cumulative DAS28-ESR. (B) Sensitivity, specificity, and cut-off values for clinical parameters predicting occurrence of RP. mTSS: modified total Sharp score, SJC: swollen joint count, TJC: tender joint count, DAS28: Disease Activity Score 28, ESR: erythrocyte sedimentation rate.
|
Table 3
Baseline and cumulative variables associated with the occurrence of radiographic progression
| Variable | Uni-variable (not adjusted) | Model 1* (uni-variable) | Model 2† (multi-variable) | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Odds ratio | 95% CI | p-value | Odds ratio | 95% CI | p-value | Odds ratio | 95% CI | p-value | |||
| Baseline mTSS | 1.024 | 1.007~1.041 | 0.022 | 1.036 | 1.011~1.062 | 0.004 | 1.036 | 1.010~1.063 | 0.006 | ||
| Cumulative RF (IU/mL) | 1.000 | 1.000~1.000 | 0.854 | 1.000 | 1.000~1.000 | 0.102 | |||||
| Cumulative ESR (mm/h) | 1.003 | 1.000~1.006 | 0.134 | 1.004 | 1.001~1.007 | 0.013 | 1.001 | 0.993~1.008 | 0.887 | ||
| Cumulative CRP (mg/dL) | 1.021 | 0.990~1.053 | 0.134 | 1.024 | 0.993~1.057 | 0.133 | |||||
| Cumulative TJC | 1.020 | 1.001~1.040 | 0.037 | 1.026 | 1.004~1.048 | 0.021 | 0.978 | 0.936~1.014 | 0.384 | ||
| Cumulative SJC | 1.090 | 1.029~1.155 | 0.001 | 1.099 | 1.034~1.167 | 0.002 | 1.099 | 1.019~1.185 | 0.014 | ||
| Cumulative DAS28-ESR | 1.053 | 1.013~1.095 | 0.029 | 1.060 | 1.018~1.103 | 0.005 | 1.017 | 0.894~1.156 | 0.802 | ||
| Cumulative sCD14 (pg/mL) | 1.000 | 1.000~1.000 | 0.148 | 1.000 | 1.000~1.000 | 0.245 | |||||
CI: confidence interval, mTSS: modified total Sharp score, RF: rheumatoid factor, ESR: erythrocyte sedimentation rate, CRP: C-reactive protein, TJC: tender joint count, SJC: swollen joint count, DAS28: disease activity score 28, sCD14: soluble CD14. *Model 1: adjusted for age, sex, and disease duration. †Model 2: clinical variables with p-values < 0.1 in ‘Model 1’ were included in multi-variable analysis with adjustment for age, sex, and disease duration.
Go to :
DISCUSSION
Most randomized clinical trials for RA are designed to limit potential biases. However, the main aim is to evaluate the therapeutic efficacy of target drugs, not to assess clinical relationships between disease-related parameters and RP; therefore, the results can be different from those observed in clinical practices. Here, we investigated which of the clinical and laboratory parameters used in daily clinics, and known to be related to RA disease activity, predict the presence and extent of RP in our prospective cohort. The results show that among all the clinical, laboratory, and radiographic values measured at the start of the study, baseline mTSS was the only parameter predicting the occurrence of RP with statistical significance. In sharp contrast, we found that cumulative values, including the cumulative TJC, cumulative SJC, and cumulative DAS28-ESR, were the major factors to determine RP. In particular, the cumulative SJC showed the best predictive performance.
The RF and ACPA titers are crucial predictors of structural damage specifically in newly diagnosed or early RA patients [21-23]. In the present study, we found no difference in RF and ACPA titers at baseline, and the cumulative RF values between the RP (+) and RP (−) groups, suggesting that RF and ACPA status is less helpful in predicting RP. We presume that these results may be specific to our population, in which the majority of patients had a relatively long disease duration (median 6 years) and had already been treated with anti-rheumatic drugs that may affect RF and ACPA levels. Indeed, previous studies report that RF and ACPA positivity and titers are relevant to early RP during the first 3~5 years of RA [21,22]. Early application of biologic agents that repress the pathogenic activity of autoantibodies could also affect RP in real-world settings as would recent treatment strategies (e.g., T2T strategies) [24,25].
Another important question is which baseline values predict RP. In the current study, we found that baseline mTSS was the only factor that predicted the occurrence of RP. Previous studies report that radiographic damage at the time of diagnosis is a strong predictor of a poor prognosis, which supports our data [26]. Because the mTSS at a certain time-point is the result of accumulated disease activity [27], it is reasonable to assume that patients with high baseline mTSS are at higher risk of more aggressive RP at the next follow-up. It is also possible that damaged joints at the time of study entry are more susceptible to injury and inflammation, and that repetitive use may contribute to further exacerbation of radiographic severity, further increasing the risk of RP.
A single measurement of RA activity (e.g., ESR, CRP, sCD14, or DAS28-ESR) is likely to be less informative for predicting RP in the real-world, particularly in the new era of T2T strategies and biologics. Obviously, RA activity levels at the time of RA diagnosis are a major factor determining disease progression and treatment outcomes; however, several studies demonstrate the occurrence of RP despite low ESR and CRP levels, indicating that low levels of such parameters do not guarantee lack of progression [28]. Single measurements of DAS28 also exhibit a similar trend [12], which is consistent with our data. Here, we tried to suppress the RA flare as much as possible by applying new or different bDMARDs and tsDMARDs immediately. Therefore, in the clinical settings of our tertiary referral hospital, baseline levels of ESR, CRP, and DAS28 are tightly controlled below the cut-off level for almost all patients throughout the study periods. Most subjects, almost 80% in fact, reached the goal of treatment, defined as remission or LDA; the median values for the baseline ESR, CRP, and DAS28 were less than the upper limit of LDA, even in the RP (+) group (Table 2). In specific situations of ‘after reaching T2T’, the clinical and laboratory parameters that predict further progression of RA should be determined.
Here, we demonstrated that cumulative values, including the cumulative TJC, cumulative SJC, and cumulative DAS28-ESR, showed a significant association with RP, suggesting that they are a good surveillance marker for RP, even after the achievement of T2T. Although some studies suggest that time-integrated cumulative values for several clinical and laboratory parameters correlate well with RP, most have not made a direct comparison between various clinical parameters [14]. The present study shows that the cumulative SJC correlated best with RP, indicating that it could be the most relevant factor for predicting RP. Unfortunately, due to lack of clinical information in our cohort, it remains unclear whether the location of the swollen joints has an effect on RP. It is intriguing that cumulative blood biomarkers, such as the cumulative ESR and CRP, were not predictive of RP, emphasizing that physical examinations should be conducted regularly to measure the DAS28 and stressing the need for alternative blood biomarkers that better predict patient outcome.
The study has several limitations. First, because all data were collected from a pre-existing cohort not for this study, there is a possibility of selection bias. Specifically, treatment regimens applied in patients of this study were relatively skewed toward non-TNF bDMARDs such as tocilizumab and abatacept. This point can affect the overall results of this study. Second, we could not control all possible confounding factors, although the demographics of the two study groups were similar between the statistical adjustments. For instance, time when csDMARDs or bDMARDs started or previous history of multiple biologic refractoriness can potentially influence cumulative disease activity, consequently determining radiographic progression. However, all such factors could not be controlled by the statistical adjustments in this study. Third, we did not evaluate other composite indices of RA activity, such as the SDAI and CDAI. Last, the number of patients and period of follow-up for RP are insufficient to make a strong conclusion. In this regard, a large-scale prospective study over a longer duration is required.
Notwithstanding these limitations, this study has several strengths. First, this is the first RP study conducted in the ‘post-biologic’ era primarily comprising RA patients taking bDMARDs and tsDMARDs, or those requiring multiple csDMARDs; this is a good reflection of current treatment paradigms and guidelines. Second, given that patient selection in randomized controlled trials tends to include subjects with HDA, which can limit generalizability, the real-world nature of this study may make the results more generalizable to daily clinical practice, although it does not eliminate concerns about confounding factors. Third, to the best of our knowledge, this is the first study in which almost all parameters potentially influencing RP at presentation and their cumulative values during follow-up were compared simultaneously and analyzed systematically.
Go to :
CONCLUSION
Clinical practice in most countries is based on current recommendations proposed by the ACR and EULAR [24,25]. We certainly aimed to achieve at least LDA during RA treatment, but we cannot rely on activity-free status determined by the current composite indices (including DAS28) because RP can occur to some extent despite a good treatment response according to these indices. The present study highlights the importance of measuring cumulative indices in addition to physical examination of swollen joints when predicting RA progression. Specifically, dynamic and cumulative values of RA activity-related factors, including cumulative DAS28, ESR, and CRP levels, are the major factors that determine RP in real practice. The cumulative SJC showed the best predictive performance for RP. A single measurement of clinical indices at a specific time-point might be less informative for predicting RA progression, particularly in patients being treated with anti-rheumatic drugs, including biologics.
Go to :
XML Download